EdgarLookup

NEOGEN CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that NEOGEN CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-122.1%
Profit Margin
Net income ÷ revenue
-31.7%
Return on Assets
Net income ÷ assets
0.66x
Debt-to-Equity
Total liabilities ÷ equity
-3.2%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $894.66M Jul 30, 2025
FY2025 May 31, 2024 $924.22M Jul 30, 2025
FY2025 May 31, 2023 $822.45M Jul 30, 2025
FY2024 May 31, 2022 $527.16M Jul 30, 2024
FY2023 May 31, 2021 $468.46M Aug 15, 2023
FY2022 May 31, 2020 $418.17M Jul 27, 2022
FY2021 May 31, 2019 $414.19M Jul 30, 2021
FY2020 May 31, 2018 $397.93M Jul 30, 2020
FY2019 May 31, 2017 $358.28M Jul 30, 2019
FY2018 May 31, 2016 $321.28M Jul 27, 2018

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 May 31, 2017 $98.85M Jul 28, 2017
FY2017 Feb 28, 2017 $88.39M Jul 28, 2017
FY2017 Nov 30, 2016 $90.72M Jul 28, 2017
FY2017 Aug 31, 2016 $83.65M Jul 28, 2017
FY2017 May 31, 2016 $90.08M Jul 28, 2017
FY2017 Feb 29, 2016 $76.73M Jul 28, 2017
FY2017 Nov 30, 2015 $79.61M Jul 28, 2017
FY2017 Aug 31, 2015 $74.86M Jul 28, 2017
FY2016 May 31, 2015 $78.61M Jul 29, 2016
FY2016 Feb 28, 2015 $68.41M Jul 29, 2016

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $421.38M Jul 30, 2025
FY2025 May 31, 2024 $463.90M Jul 30, 2025
FY2025 May 31, 2023 $405.96M Jul 30, 2025
FY2024 May 31, 2022 $243.01M Jul 30, 2024
FY2021 May 31, 2021 $57.69M Jul 30, 2021
FY2021 Feb 28, 2021 $53.85M Jul 30, 2021
FY2021 Nov 30, 2020 $53.21M Jul 30, 2021
FY2021 Aug 31, 2020 $50.30M Jul 30, 2021
FY2021 May 31, 2020 $51.73M Jul 30, 2021
FY2021 Feb 29, 2020 $45.33M Jul 30, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 ($1.09B) Jul 30, 2025
FY2025 May 31, 2024 ($9.42M) Jul 30, 2025
FY2025 May 31, 2023 ($22.87M) Jul 30, 2025
FY2024 May 31, 2022 $48.31M Jul 30, 2024
FY2023 May 31, 2021 $60.88M Aug 15, 2023
FY2022 May 31, 2020 $59.48M Jul 27, 2022
FY2021 May 31, 2019 $60.18M Jul 30, 2021
FY2019 May 31, 2018 $17.55M Jul 30, 2019
FY2019 Feb 28, 2018 $16.59M Jul 30, 2019
FY2019 Nov 30, 2017 $17.10M Jul 30, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 ($1.06B) Jul 30, 2025
FY2025 May 31, 2024 $58.66M Jul 30, 2025
FY2025 May 31, 2023 $37.52M Jul 30, 2025
FY2024 May 31, 2022 $58.62M Jul 30, 2024
FY2023 May 31, 2021 $74.17M Aug 15, 2023
FY2022 May 31, 2020 $67.52M Jul 27, 2022
FY2021 May 31, 2019 $68.09M Jul 30, 2021
FY2020 May 31, 2018 $70.19M Jul 30, 2020
FY2019 May 31, 2017 $64.95M Jul 30, 2019
FY2018 May 31, 2016 $56.39M Jul 27, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $21.09M Jul 30, 2025
FY2025 May 31, 2024 $22.48M Jul 30, 2025
FY2025 May 31, 2023 $26.04M Jul 30, 2025
FY2024 May 31, 2022 $17.05M Jul 30, 2024
FY2023 May 31, 2021 $16.25M Aug 15, 2023
FY2022 May 31, 2020 $14.75M Jul 27, 2022
FY2021 May 31, 2019 $12.81M Jul 30, 2021
FY2020 May 31, 2018 $10.86M Jul 30, 2020
FY2019 May 31, 2017 $10.39M Jul 30, 2019
FY2018 May 31, 2016 $9.89M Jul 27, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $58.24M Jul 30, 2025
FY2025 May 31, 2024 $35.26M Jul 30, 2025
FY2025 May 31, 2023 $41.03M Jul 30, 2025
FY2024 May 31, 2022 $68.04M Jul 30, 2024
FY2023 May 31, 2021 $81.09M Aug 15, 2023
FY2022 May 31, 2020 $85.88M Jul 27, 2022
FY2021 May 31, 2019 $63.84M Jul 30, 2021
FY2020 May 31, 2018 $69.13M Jul 30, 2020
FY2019 May 31, 2017 $60.27M Jul 30, 2019
FY2018 May 31, 2016 $35.33M Jul 27, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2013 Dec 31, 2012 $1.50M Jul 30, 2013
FY2012 May 31, 2012 $1.50M Jul 30, 2012
FY2012 Aug 31, 2011 $4.95M Jul 30, 2012

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $3.44B Jul 30, 2025
FY2025 May 31, 2024 $4.55B Jul 30, 2025
FY2025 May 31, 2023 $4.55B Jul 30, 2025
FY2024 May 31, 2022 $992.93M Jul 30, 2024
FY2023 May 31, 2021 $920.19M Aug 15, 2023
FY2022 May 31, 2020 $797.18M Jul 27, 2022
FY2021 May 31, 2019 $695.74M Jul 30, 2021
FY2020 May 31, 2018 $618.01M Jul 30, 2020
FY2019 May 31, 2017 $528.41M Jul 30, 2019
FY2018 May 31, 2016 $449.94M Jul 27, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $1.37B Jul 30, 2025
FY2025 May 31, 2024 $1.40B Jul 30, 2025
FY2024 May 31, 2023 $1.42B Jul 30, 2024
FY2023 May 31, 2022 $105.56M Aug 15, 2023
FY2022 May 31, 2021 $79.82M Jul 27, 2022
FY2021 May 31, 2020 $72.01M Jul 30, 2021
FY2020 May 31, 2019 $57.84M Jul 30, 2020
FY2019 May 31, 2018 $57.83M Jul 30, 2019
FY2018 May 31, 2017 $56.65M Jul 27, 2018
FY2017 May 31, 2016 $45.78M Jul 28, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $2.07B Jul 30, 2025
FY2025 May 31, 2024 $3.14B Jul 30, 2025
FY2024 May 31, 2023 $3.13B Jul 30, 2024
FY2023 May 31, 2022 $887.37M Aug 15, 2023
FY2022 May 31, 2021 $840.38M Jul 27, 2022
FY2021 May 31, 2020 $725.18M Jul 30, 2021
FY2020 May 31, 2019 $637.90M Jul 30, 2020
FY2019 May 31, 2018 $560.18M Jul 30, 2019
FY2018 May 31, 2017 $471.61M Jul 27, 2018
FY2017 May 31, 2016 $404.20M Jul 28, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $1.06B Jul 30, 2025
FY2025 May 31, 2024 $2.14B Jul 30, 2025
FY2025 May 31, 2023 $2.14B Jul 30, 2025
FY2024 May 31, 2022 $142.70M Jul 30, 2024
FY2023 May 31, 2021 $131.48M Aug 15, 2023
FY2022 May 31, 2020 $110.34M Jul 27, 2022
FY2021 May 31, 2019 $103.62M Jul 30, 2021
FY2020 May 31, 2018 $99.56M Jul 30, 2020
FY2019 May 31, 2017 $104.76M Jul 30, 2019
FY2018 May 31, 2016 $88.51M Jul 27, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 ($536.42M) Jul 30, 2025
FY2025 May 31, 2024 $555.62M Jul 30, 2025
FY2024 May 31, 2023 $565.04M Jul 30, 2024
FY2023 May 31, 2022 $587.91M Aug 15, 2023
FY2022 May 31, 2021 $539.60M Jul 27, 2022
FY2021 May 31, 2020 $478.72M Jul 30, 2021
FY2020 May 31, 2019 $419.25M Jul 30, 2020
FY2019 May 31, 2018 $359.07M Jul 30, 2019
FY2018 May 31, 2017 $295.93M Jul 27, 2018
FY2017 May 31, 2016 $252.13M Jul 28, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $129.00M Jul 30, 2025
FY2025 May 31, 2024 $170.61M Jul 30, 2025
FY2024 May 31, 2023 $163.24M Jul 30, 2024
FY2023 May 31, 2022 $44.47M Aug 15, 2023
FY2022 May 31, 2021 $75.60M Jul 27, 2022
FY2021 May 31, 2020 $66.27M Jul 30, 2021
FY2021 May 31, 2019 $41.69M Jul 30, 2021
FY2021 May 31, 2018 $83.07M Jul 30, 2021
FY2020 May 31, 2017 $77.57M Jul 30, 2020
FY2019 May 31, 2016 $55.26M Jul 30, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 (5) Jul 30, 2025
FY2025 May 31, 2024 0 Jul 30, 2025
FY2025 May 31, 2023 0 Jul 30, 2025
FY2024 May 31, 2022 0 Jul 30, 2024
FY2021 May 31, 2021 0 Jul 30, 2021
FY2021 Feb 28, 2021 0 Jul 30, 2021
FY2021 Nov 30, 2020 0 Jul 30, 2021
FY2021 Aug 31, 2020 0 Jul 30, 2021
FY2021 May 31, 2020 0 Jul 30, 2021
FY2021 Feb 29, 2020 0 Jul 30, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 (5) Jul 30, 2025
FY2025 May 31, 2024 0 Jul 30, 2025
FY2025 May 31, 2023 0 Jul 30, 2025
FY2024 May 31, 2022 0 Jul 30, 2024
FY2021 May 31, 2021 0 Jul 30, 2021
FY2021 Feb 28, 2021 0 Jul 30, 2021
FY2021 Nov 30, 2020 0 Jul 30, 2021
FY2021 Aug 31, 2020 0 Jul 30, 2021
FY2021 May 31, 2020 0 Jul 30, 2021
FY2021 Feb 29, 2020 0 Jul 30, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 216.61M Jul 30, 2025
FY2025 May 31, 2024 217.04M Jul 30, 2025
FY2024 May 31, 2023 216.25M Jul 30, 2024
FY2023 May 31, 2022 107.80M Aug 15, 2023
FY2022 May 31, 2021 107.47M Jul 27, 2022
FY2021 May 31, 2020 105.89M Jul 30, 2021
FY2020 May 31, 2019 52.22M Jul 30, 2020
FY2019 May 31, 2018 51.74M Jul 30, 2019
FY2018 May 31, 2017 50.93M Jul 27, 2018
FY2017 May 31, 2016 37.57M Jul 28, 2017